Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Summit Therapeutics (SMMT) over the last 7 years, with Q3 2025 value amounting to $2.0 million.

  • Summit Therapeutics' Other Accumulated Expenses rose 9045.76% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 9045.76%. This contributed to the annual value of $1.8 million for FY2024, which is 15062.76% up from last year.
  • Summit Therapeutics' Other Accumulated Expenses amounted to $2.0 million in Q3 2025, which was up 9045.76% from $1.5 million recorded in Q2 2025.
  • Summit Therapeutics' Other Accumulated Expenses' 5-year high stood at $2.0 million during Q3 2025, with a 5-year trough of $209000.0 in Q3 2022.
  • Its 5-year average for Other Accumulated Expenses is $828473.7, with a median of $717000.0 in 2023.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 19096.05% in 2021, then crashed by 7970.87% in 2022.
  • Quarter analysis of 5 years shows Summit Therapeutics' Other Accumulated Expenses stood at $897000.0 in 2021, then decreased by 26.2% to $662000.0 in 2022, then rose by 8.31% to $717000.0 in 2023, then skyrocketed by 150.63% to $1.8 million in 2024, then increased by 8.85% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $1.5 million for Q2 2025, and $759000.0 during Q1 2025.